Managing anemia in the more than 80 percent of chronic kidney disease patients who experience it is the goal of a reported Mayo Clinic health IT spinoff.
Anemia in renal failure is caused primarily by inadequate production of erythropoietin, a hormone that stimulates the production of red blood cells. Physician Software Systems LLC‘s technology helps manage individualized dosing of erythropoiesis-stimulation agents to lessen the risk of anemia, weakness, thrombosis, stroke and cardiovascular events associated with unstable hemoglobin levels. It’s intended for use in patients undergoing hemodialysis, a blood-filtering process that’s the most common method used to treat chronic kidney disease.
Physician Software Systems is looking to raise $1.3 million in equity, as disclosed in a recent U.S. Securities and Exchange Commission filing. According to the May Report, the company was formed in 2011 to commercialize technology developed at Mayo Clinic. An email inquiry sent to the company for further detail on progress and upcoming milestones went unreturned.
The market potential for such technology seems uncertain. A BCC Research market report on renal failure treatments indicates a growing market for chronic kidney disease treatments that’s expected to reach $31.7 billion by 2014. But Nephrology News & Issues and GlobalData report that use of anemia drugs has declined in recent years due to safety concerns with ESAs and modified dosing guidelines released by the U.S. Food and Drug Administration in 2011.
The company is based in Lisle, Illinois.
